Stifel Nicolaus Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective lifted by equities researchers at Stifel Nicolaus from $200.00 to $207.00 in a report released on Friday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Stifel Nicolaus’ price objective points to a potential upside of 63.62% from the company’s previous close.

A number of other research firms have also issued reports on ASND. Bank of America boosted their target price on Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Oppenheimer reaffirmed an “outperform” rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. The Goldman Sachs Group boosted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Wedbush restated an “outperform” rating and set a $181.00 target price on shares of Ascendis Pharma A/S in a report on Friday. Finally, JPMorgan Chase & Co. lowered their target price on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $126.51 on Friday. The business has a fifty day moving average price of $132.30 and a 200 day moving average price of $132.66. The stock has a market capitalization of $7.67 billion, a P/E ratio of -13.59 and a beta of 0.66. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -7.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the company. Signaturefd LLC lifted its holdings in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Bessemer Group Inc. lifted its position in Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares during the period. Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S during the third quarter worth about $217,000. Searle & CO. purchased a new stake in Ascendis Pharma A/S in the 2nd quarter worth $205,000. Finally, Rhumbline Advisers raised its position in shares of Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 143 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.